The anti-tumor effects of entinostat in ovarian cancer require adaptive immunity

BACKGROUND: Ovarian cancer is poorly immunogenic; however, increased major histocompatibility complex class II (MHCII) expression correlates with improved immune response and prolonged survival in ovarian cancer patients. We previously demonstrated that the histone deacetylase inhibitor entinostat i...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer
Egile Nagusiak: Smith, Haller J., McCaw, Tyler R., Londono, Angelina I., Katre, Ashwini A., Meza-Perez, Selene, Yang, Eddy S., Forero, Andres, Buchsbaum, Donald J., Randall, Troy D., Straughn, J. Michael, Norian, Lyse A., Arend, Rebecca C.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6294677/
https://ncbi.nlm.nih.gov/pubmed/30423192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31761
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak